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The concept of cancer stem cells has generated signiﬁ-
cant interests among cancer researchers. This has led to
proliferative number of publications on the subject in
the recent years and eventually controversies because of
conﬂicting data in the literature. As we try to ﬁnd relevance
of the stem cell concept to various aspects of cancer
biology, we also discover individual diﬀerences that drive
the cancer stemness. Nevertheless, the concept of cancer
stem cell is likely to stay and is already making huge
impact as we develop novel diagnostics and therapeutics for
cancer.
In this special issue, we selected reviews on the unique
stem cell biology in breast cancer, head and neck cancer,
lung cancer, and brain malignancy and touched the topic of
therapeutic resistance as a consequence of cancer stem cells.
Individual research papers were also selected to demonstrate
the relevance of cancer stem cells to cancer metastasis and
apoptosis.
As we embrace the concept of cancer stem cells, it is
important to realize its limitations. We have learnt that
antiangiogenic drugs that attack tumor blood vessels, an
important aspect of cancer biology, have not been able to
cure cancer and may cause unique side eﬀects in patients.
By the same token, toxicities are of concern when the stem
cells of normal tissues are injured by agents that target stem
cell pathways. With this issue, we aim to provoke discussion
andawareness ofcancerstemcellbiology,assomeofresearch
ﬁndings are being translated and making their way to our
oncology practice.
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